Search

Displaying results 1291 - 1300 of 10000 in total
  1. Drug

    Idecabtagene vicleucel

    go.drugbank.com/drugs/DB16665
    ApprovedInvestigational

    [A232558,A232563,L32858] These therapies involve extracting and genetically manipulating T-cells from a patient to express a CAR for a tumor specific antigen. … [A232563] Multiple myeloma is typically treated with an immunomodulatory agent like [lenalidomide],[A232593] a proteasome inhibitor like [bortezomib], or an anti-CD38 monoclonal antibody like [isatuximab

  2. Drug

    Tulmimetostat

    go.drugbank.com/drugs/DB19446
    Investigational

    Tulmimetostat is under investigation in clinical trial NCT05467748 (EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer).

  3. Drug

    Pirepemat

    go.drugbank.com/drugs/DB19165
    Investigational

    Pirepemat is under investigation in clinical trial NCT05258071 (A Clinical Study Evaluating Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Disease (PD)).

  4. Drug

    Hepatitis A Vaccine

    go.drugbank.com/drugs/DB10989
    ApprovedInvestigational

    [A199182] Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infection and safely confers strong protection … Hepatitis A viral infection can lead to significant morbidity and mortality, with signs and symptoms that include anorexia, nausea, vomiting, and liver failure.

    Synonyms: Hepatitis A Vaccine, Hepatitis A vaccine, inactivatedSalts: Hepatitis A virus strain CR 326F antigen (formaldehyde inactivated), Hepatitis A virus strain HM175 antigen (formaldehyde inactivated)
  5. Drug

    Sirolimus

    go.drugbank.com/drugs/DB00877
    ApprovedInvestigational

    extensively investigated as an immunosuppressive and antitumour agent. … survival. mTOR is an important therapeutic target for various diseases, as it was shown to regulate longevity and maintain normal glucose homeostasis.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: P-HYSPLAN
  6. Drug

    AP5280

    go.drugbank.com/drugs/DB05112
    Experimental

    AP5280 is a novel N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound platinum (Pt) therapeutic designed to increase the therapeutic index relative to conventional, small-molecule platinum agents.

  7. Drug

    Telisotuzumab vedotin

    go.drugbank.com/drugs/DB15104
    ApprovedInvestigational

    Telisotuzumab vedotin is an antibody-drug conjugate comprising [telisotuzumab], a c-Met-directed humanized IgG1κ monoclonal antibody, conjugated to monomethyl auristatin E (MMAE), a small molecule microtubule-disrupting … agent, via a protease-cleavable valine-citrulline linker.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inhibitors
  8. Drug

    Hydroxypropyl cellulose

    go.drugbank.com/drugs/DB00840
    Approved

    As a food additive, hydroxypropyl cellulose is used as a thickener and as an emulsion stabilizer. … a lubricant for artificial eyes.

    Categories: Compounds used in a research, industrial, or household settingInternational brands: A-Gel
  9. Drug

    Domagrozumab

    go.drugbank.com/drugs/DB15083
    Investigational

    Domagrozumab is under investigation in clinical trial NCT01616277 (A Phase 1 Study To Evaluate The Safety And Tolerability Of PF-06252616 In Healthy Subjects).

    Synonyms: PF-06252616
  10. Drug

    Metrizoic acid

    go.drugbank.com/drugs/DB09346
    Approved

    Metrizoic acid is a molecule used as a contrast medium. It present a higher risk of allergic reactions due to its high osmolality. Its approval has been discontinued by the FDA. … A total of 10, 000 injections were administered to 2,028 patients undergoing angiocardiographic procedures over a three-year period.

    Categories: Compounds used in a research, industrial, or household setting